Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2010-02-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10549-010-0763-9PMID 20135346
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ATX-LPA receptor axis in inflammation and cancer

  2009cited by this paper
• Phosphorylation of IRS proteins, insulin action, and insulin resistance.

  2009cited by this paper
• The Pharmacology of mTOR Inhibition

  2009cited by this paper
• LKB1 and AMP‐activated protein kinase control of mTOR signalling and growth

  2009cited by this paper
• Metformin induces unique biological and molecular responses in triple negative breast cancer cells

  2009cited by this paper
• A PP2A regulatory subunit regulates C. elegans insulin/IGF-1 signaling by modulating AKT-1 phosphorylation.

  2009cited by this paper
• Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.

  2009cited by this paper
• From promiscuity to precision: protein phosphatases get a makeover.

  2009cited by this paper
• Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth.

  2008cited by this paper
• The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase

  2008cited by this paper
• AMPK phosphorylation of raptor mediates a metabolic checkpoint.

  2008cited by this paper
• Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1

  2008cited by this paper
• Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.

  2008cited by this paper
• Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

  2008cited by this paper
• Insulin and insulin-like growth factor signalling in neoplasia

  2008cited by this paper
• AMPK and Raptor: matching cell growth to energy supply.

  2008cited by this paper
• Defining the role of mTOR in cancer.

  2007cited by this paper
• Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.

  2007cited by this paper
• Energy Depletion Inhibits Phosphatidylinositol 3-Kinase/Akt Signaling and Induces Apoptosis via AMP-activated Protein Kinase-dependent Phosphorylation of IRS-1 at Ser-794*

  2007cited by this paper
• Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.

  2007cited by this paper
• AKT/PKB signaling: navigating downstream.

  2007cited by this paper
• The two TORCs and Akt.

  2007cited by this paper
• IRS-1: auditing the effectiveness of mTOR inhibitors.

  2006cited by this paper
• Nutrients Suppress Phosphatidylinositol 3-Kinase/Akt Signaling via Raptor-Dependent mTOR-Mediated Insulin Receptor Substrate 1 Phosphorylation

  2006cited by this paper
• mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

  2006cited by this paper
• Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

  2006cited by this paper
• Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

  2005cited by this paper
• Positive and negative regulation of insulin signaling through IRS-1 phosphorylation.

  2005cited by this paper
• The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins

  2004cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• Role of mTOR in the degradation of IRS‐1: Regulation of PP2A activity

  2002cited by this paper
• A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1

  2001cited by this paper
• 5′-AMP-activated Protein Kinase Phosphorylates IRS-1 on Ser-789 in Mouse C2C12 Myotubes in Response to 5-Aminoimidazole-4-carboxamide Riboside*

  2001influential reference

• Ferulic Acid from Beta vulgaris subsp. vulgaris Altissima Group Pulp Targets the CaMKKβ/SIRT-1/AMPK Pathway To Combat Hyperglycemia.

  2025cites this paper
• Exploring the interactions of rapamycin with target receptors in A549 cancer cells: insights from molecular docking analysis

  2025cites this paper
• Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights

  2025cites this paper
• A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer.

  2025cites this paper
• Metformin and myo-inositol: A comparative analysis.

  2025cites this paper
• Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial

  2025cites this paper
• Plant‐Based Anticancer Compounds With a Focus on Breast Cancer

  2024cites this paper
• Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways

  2024cites this paper
• SignalingProfiler 2.0: a network-based approach to bridge multi-omics data to phenotypic hallmarks

  2024cites this paper
• Progestin-based pharmacotherapy in fertility preservation in early endometrial cancer

  2024cites this paper
• Anti-cancer activity of Mebendazole, Metformin and Apricoxib in HT-29, MDA-MB-231 HelaandMCF-7cell lines: Preclinical trial

  2023cites this paper
• Evaluation of the Combination of Metformin and Rapamycin in an MPP+-Treated SH-SY5Y Model of Parkinson's Disease

  2023cites this paper
• The antidiabetic effect of superparamagnetic iron oxide nanoparticles highlights the role of WNT/AMPK/mTOR/FOXO1/mitochondrial DNA in muscle and kidney.

  2023cites this paper
• Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

  2023cites this paper
• Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors

  2023cites this paper
• The development and benefits of metformin in various diseases

  2023cites this paper
• Liraglutide attenuates obese-associated breast cancer cell proliferation via inhibiting PI3K/Akt/mTOR signaling pathway

  2023cites this paper
• Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma

  2023cites this paper
• The potential therapeutic impact of metformin in glioblastoma multiforme.

  2022cites this paper
• Advanced and recurrent endometrial cancer: state of the art and future perspectives.

  2022cites this paper
• Metformin and Cancer, an Ambiguanidous Relationship

  2022cites this paper
• Sera from women with different metabolic and menopause states differentially regulate cell viability and Akt activation in a breast cancer in-vitro model

  2022cites this paper
• Metformin induces mitochondrial remodeling and differentiation of pancreatic progenitor cells into beta-cells by a potential mechanism including suppression of the T1R3, PLCβ2, cytoplasmic Ca+2, and AKT

  2022cites this paper
• Exploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases

  2022cites this paper
• The crosstalk within the breast tumor microenvironment in type II diabetes: Implications for cancer disparities

  2022cites this paper
• PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy

  2022cites this paper
• The Effect of Metformin on SIK1 and SIK2 in MCF-7 Cell as an Anticancer Agent

  2022cites this paper
• Biguanides drugs: Past success stories and promising future for drug discovery.

  2021cites this paper
• Metformin inhibits the proliferation of canine mammary gland tumor cells through the AMPK/AKT/mTOR signaling pathway in vitro

  2021cites this paper
• Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition

  2021cites this paper
• Spelling Out CICs: A Multi-Organ Examination of the Contributions of Cancer Initiating Cells’ Role in Tumor Progression

  2021cites this paper
• Effects of metformin on experimentally induced acne on rabbit ear

  2021cites this paper
• Plant Derived Bioactive Compounds, Their Anti-Cancer Effects and In Silico Approaches as an Alternative Target Treatment Strategy for Breast Cancer: An Updated Overview

  2021cites this paper
• Repurposing metformin for the treatment of gastrointestinal cancer

  2021cites this paper
• Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy

  2020cites this paper
• Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer

  2020cites this paper
• Opposite estrogen effects of estrone and 2-hydroxyestrone on MCF-7 sensitivity to the cytotoxic action of cell growth, oxidative stress and inflammation activity.

  2020cites this paper
• Mechanisms of action of metformin and its regulatory effect on microRNAs related to angiogenesis.

  2020cites this paper
• Efficacy of Metformin and Chemotherapeutic Agents on the Inhibition of Colony Formation and Shh/Gli1 Pathway: Metformin/Docetaxel Versus Metformin/5-Fluorouracil

  2020cites this paper
• Metabolism and immunity in breast cancer

  2020cites this paper
• Pharmacological interventions part IV: Metabolic modifiers

  2020cites this paper
• Metformin as Potential Therapy for High-Grade Glioma

  2020cites this paper
• Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer

  2020cites this paper
• Synergistic therapeutic effects of metformin at a clinically relevant dosage in combination with chemotherapy via the AKT/mTOR pathway on ovarian cancer

  2019cites this paper
• Breast Cancer Prevention

  2019cites this paper
• The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases

  2019cites this paper
• Specific diacylglycerols generated by hepatic lipogenesis stimulate the oncogenic androgen receptor activity in male hepatocytes

  2019cites this paper
• Metformin Induces Apoptosis and Inhibits Proliferation through the AMP-Activated Protein Kinase and Insulin-like Growth Factor 1 Receptor Pathways in the Bile Duct Cancer Cells

  2019cites this paper
• mTORC2/Akt activation in adipocytes is required for adipose tissue inflammation in tuberculosis

  2019influential citation
• Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer

  2019cites this paper
• Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin

  2019cites this paper
• The role of metformin and statins in ovarian and breast cancer in women with type 2 diabetes

  2019cites this paper
• MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation.

  2019cites this paper
• The role of the antidiabetic drug metformin in the treatment of endocrine tumors.

  2019cites this paper
• Bifurcation analysis of insulin regulated mTOR signalling pathway in cancer cells.

  2018influential citation
• The Therapeutic Potential of Metformin in Neurodegenerative Diseases

  2018cites this paper
• Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them

  2018cites this paper
• IMPACT OF AMPK ACTIVATOR METFORMIN ON SPERM QUALITY

  2018cites this paper
• Survival of the fittest: Cancer challenges T cell metabolism.

  2018cites this paper
• A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors

  2018cites this paper
• Higenamine enhances the antitumor effects of cucurbitacin B in breast cancer by inhibiting the interaction of AKT and CDK2.

  2018cites this paper
• Effects of metformin on endometrial cancer: Systematic review and meta-analysis.

  2017cites this paper
• Evaluating Metformin as a Potential Chemosensitizing Agent when Combined with Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Cells.

  2017cites this paper
• PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer

  2017cites this paper
• MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway

  2017cites this paper
• Protopanaxadiol and metformin synergistically inhibit estrogen-mediated proliferation and anti-autophagy effects in endometrial cancer cells.

  2017cites this paper
• Survival of the fittest : Cancer challenges T 1 cell metabolism 2 3

  2017cites this paper
• Treatment strategies for endometrial cancer: current practice and perspective

  2017cites this paper
• ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway

  2017cites this paper
• Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer

  2017cites this paper
• Combination of metformin with chemotherapeutic drugs via different molecular mechanisms.

  2017cites this paper
• A story of metformin‐butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug?

  2017cites this paper
• Metformin targets multiple signaling pathways in cancer

  2017cites this paper
• Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells

  2017cites this paper
• Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo.

  2017cites this paper
• Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials

  2017cites this paper
• Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient–Derived Xenografts

  2017cites this paper
• A phase Ib study of everolimus combined with metformin for patients with advanced cancer

  2017cites this paper
• Dietary rapamycin supplementation reverses age‐related vascular dysfunction and oxidative stress, while modulating nutrient‐sensing, cell cycle, and senescence pathways

  2016cites this paper
• Metformin inhibits estrogen‐dependent endometrial cancer cell growth by activating the AMPK–FOXO1 signal pathway

  2016cites this paper
• Repurposing metformin for cancer treatment: current clinical studies

  2016cites this paper
• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.

  2016cites this paper
• Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers

  2016cites this paper
• Combinational strategies of metformin and chemotherapy in cancers

  2016cites this paper
• Metformin Protects Kidney Cells From Insulin-Mediated Genotoxicity In Vitro and in Male Zucker Diabetic Fatty Rats.

  2016cites this paper
• Molecular targets of metformin antitumor action

  2016cites this paper
• Combination Therapies Targeting the PI3K/AKT/mTOR Pathways

  2016cites this paper
• Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates.

  2016cites this paper
• Rescue of mutant rhodopsin traffic by metformin-induced AMPK activation accelerates photoreceptor degeneration

  2016cites this paper
• Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival

  2016cites this paper
• Genomic and morphoproteomic correlates implicate the IGF-1/mTOR/Akt pathway in the pathogenesis of diffuse congenital hyperinsulinism

  2016cites this paper
• On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer

  2016cites this paper
• Morphoproteomics Identifies Etiopathogenetic Correlates of HHV-8-Associated Kaposi's Sarcoma and Provides Pathways with Therapeutic Options: A Case Study.

  2016cites this paper
• Measuring the biological effect of presurgical metformin treatment in endometrial cancer

  2016cites this paper
• AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs.

  2016cites this paper
• Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer

  2016cites this paper
• Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis and therapeutic options

  2016cites this paper
• Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin

  2016cites this paper
• Peran Metformin sebagai Inhibitor Jaras Insulin-like Growth Factor-1 Receptor (IGF-1R), Epidermal Growth Factor Receptor (EGFR), dan Mammalian Target of Rapamycin (mTOR) pada Kemoterapi Kanker Paru

  2016cites this paper
• Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options

  2016cites this paper